Peginterferon-α2b and ribavirin

Joseph Ahn, Steven Flamm

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Hepatitis C virus infection is among the leading causes of chronic liver disease in the USA and has a worldwide prevalence of approximately 300 million people. Chronic hepatitis C virus is the most common indication for liver transplantation in the USA. Due to the chronic nature of hepatitis C virus infection, these numbers are expected to grow fourfold in the next decade. Interferon-α2b monotherapy followed by combination therapy with ribavirin have been used to treat chronic hepatitis C virus with limited success. The development of pegylated interferon-α2b, (Peg-intron®, Schering-Plough) instituted the next chapter in hepatitis C virus therapy. The demonstration of its safety and efficacy led to a major trial studying coadministration with ribavirin for compensated chronic hepatitis C virus infection. Pegylated interferon combination therapy has improved efficacy over standard interferon combination therapy without an increase in adverse effects. This article reviews the data regarding pegylated interferon-α2b with ribavirin therapy. The pharmacokinetics and pharmacodynamics of combination therapy will be presented along with clinical trial data. The efficacy and ease of usage of Pegintron and ribavirin support its use for chronic hepatitis C virus infection.

Original languageEnglish (US)
Pages (from-to)17-25
Number of pages9
JournalExpert Review of Anti-Infective Therapy
Volume2
Issue number1
StatePublished - Feb 2004
Externally publishedYes

Fingerprint

Ribavirin
Hepacivirus
Chronic Hepatitis C
Interferons
Virus Diseases
Therapeutics
Liver Transplantation
Introns
Liver Diseases
Chronic Disease
Pharmacokinetics
Clinical Trials
Safety

Keywords

  • HCV
  • Interferon
  • Pegintron
  • Pegylated interferon
  • Ribavirin

ASJC Scopus subject areas

  • Infectious Diseases
  • Parasitology

Cite this

Peginterferon-α2b and ribavirin. / Ahn, Joseph; Flamm, Steven.

In: Expert Review of Anti-Infective Therapy, Vol. 2, No. 1, 02.2004, p. 17-25.

Research output: Contribution to journalArticle

Ahn, Joseph ; Flamm, Steven. / Peginterferon-α2b and ribavirin. In: Expert Review of Anti-Infective Therapy. 2004 ; Vol. 2, No. 1. pp. 17-25.
@article{ed149069d33c464bad5b4cbdf4de9b9f,
title = "Peginterferon-α2b and ribavirin",
abstract = "Hepatitis C virus infection is among the leading causes of chronic liver disease in the USA and has a worldwide prevalence of approximately 300 million people. Chronic hepatitis C virus is the most common indication for liver transplantation in the USA. Due to the chronic nature of hepatitis C virus infection, these numbers are expected to grow fourfold in the next decade. Interferon-α2b monotherapy followed by combination therapy with ribavirin have been used to treat chronic hepatitis C virus with limited success. The development of pegylated interferon-α2b, (Peg-intron{\circledR}, Schering-Plough) instituted the next chapter in hepatitis C virus therapy. The demonstration of its safety and efficacy led to a major trial studying coadministration with ribavirin for compensated chronic hepatitis C virus infection. Pegylated interferon combination therapy has improved efficacy over standard interferon combination therapy without an increase in adverse effects. This article reviews the data regarding pegylated interferon-α2b with ribavirin therapy. The pharmacokinetics and pharmacodynamics of combination therapy will be presented along with clinical trial data. The efficacy and ease of usage of Pegintron and ribavirin support its use for chronic hepatitis C virus infection.",
keywords = "HCV, Interferon, Pegintron, Pegylated interferon, Ribavirin",
author = "Joseph Ahn and Steven Flamm",
year = "2004",
month = "2",
language = "English (US)",
volume = "2",
pages = "17--25",
journal = "Expert Review of Anti-Infective Therapy",
issn = "1478-7210",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Peginterferon-α2b and ribavirin

AU - Ahn, Joseph

AU - Flamm, Steven

PY - 2004/2

Y1 - 2004/2

N2 - Hepatitis C virus infection is among the leading causes of chronic liver disease in the USA and has a worldwide prevalence of approximately 300 million people. Chronic hepatitis C virus is the most common indication for liver transplantation in the USA. Due to the chronic nature of hepatitis C virus infection, these numbers are expected to grow fourfold in the next decade. Interferon-α2b monotherapy followed by combination therapy with ribavirin have been used to treat chronic hepatitis C virus with limited success. The development of pegylated interferon-α2b, (Peg-intron®, Schering-Plough) instituted the next chapter in hepatitis C virus therapy. The demonstration of its safety and efficacy led to a major trial studying coadministration with ribavirin for compensated chronic hepatitis C virus infection. Pegylated interferon combination therapy has improved efficacy over standard interferon combination therapy without an increase in adverse effects. This article reviews the data regarding pegylated interferon-α2b with ribavirin therapy. The pharmacokinetics and pharmacodynamics of combination therapy will be presented along with clinical trial data. The efficacy and ease of usage of Pegintron and ribavirin support its use for chronic hepatitis C virus infection.

AB - Hepatitis C virus infection is among the leading causes of chronic liver disease in the USA and has a worldwide prevalence of approximately 300 million people. Chronic hepatitis C virus is the most common indication for liver transplantation in the USA. Due to the chronic nature of hepatitis C virus infection, these numbers are expected to grow fourfold in the next decade. Interferon-α2b monotherapy followed by combination therapy with ribavirin have been used to treat chronic hepatitis C virus with limited success. The development of pegylated interferon-α2b, (Peg-intron®, Schering-Plough) instituted the next chapter in hepatitis C virus therapy. The demonstration of its safety and efficacy led to a major trial studying coadministration with ribavirin for compensated chronic hepatitis C virus infection. Pegylated interferon combination therapy has improved efficacy over standard interferon combination therapy without an increase in adverse effects. This article reviews the data regarding pegylated interferon-α2b with ribavirin therapy. The pharmacokinetics and pharmacodynamics of combination therapy will be presented along with clinical trial data. The efficacy and ease of usage of Pegintron and ribavirin support its use for chronic hepatitis C virus infection.

KW - HCV

KW - Interferon

KW - Pegintron

KW - Pegylated interferon

KW - Ribavirin

UR - http://www.scopus.com/inward/record.url?scp=2942557181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942557181&partnerID=8YFLogxK

M3 - Article

C2 - 15482168

AN - SCOPUS:2942557181

VL - 2

SP - 17

EP - 25

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

SN - 1478-7210

IS - 1

ER -